Try a new search

Format these results:

Searched for:

in-biosketch:yes

person:morgag04

Total Results:

677


Treatment of relapsed and refractory multiple myeloma in the era of novel agents

van de Donk, Niels W C J; Lokhorst, Henk M; Dimopoulos, Meletios; Cavo, Michele; Morgan, Gareth; Einsele, Hermann; Kropff, Martin; Schey, Steve; Avet-Loiseau, Hervé; Ludwig, Heinz; Goldschmidt, Hartmut; Sonneveld, Pieter; Johnsen, Hans E; Bladé, Joan; San-Miguel, Jesús F; Palumbo, Antonio
The introduction of the Immunomodulatory drugs (IMiDs) and proteasome inhibitors, used either as a single-agent or combined with classic anti-myeloma therapies, has improved the outcome for patients with relapsed myeloma. However, there is currently no generally accepted standard treatment for relapsed/refractory myeloma patients, partly because of the absence of trials comparing the efficacy of the novel agents in relapsed/refractory myeloma. Choice of a new treatment regimen depends on both patient and disease-specific characteristics. A lenalidomide-based regimen is the first choice in patients with neuropathy, while bortezomib has the highest efficacy in patients with renal insufficiency and is not associated with increased risk of thromboembolism. A second autologous stem cell transplantation (auto-SCT) can be applied in patients with a progression-free period of ≥ 18-24 months after the first auto-SCT. In high-risk relapse such as occurring early after auto-SCT consolidation with allogeneic SCT can be considered. In this review we provide an overview of the various salvage regimens and give recommendations for treatment of patients with relapsed/refractory myeloma in different clinical settings.
PMID: 20863623
ISSN: 1532-1967
CID: 3696002

The outcome of high-dose chemotherapy and auto-SCT in patients with multiple myeloma: a UK/Ireland and European benchmarking comparative analysis

Cook, G; Jackson, G H; Morgan, G J; Russell, N; Kirkland, K; Lee, J; Pearce, R; Marks, D I; Pagliuca, A
Auto-SCT is the standard first-line consolidative therapy in patients with multiple myeloma (MM). We performed a national benchmarking outcome analysis for patients with MM who underwent a single auto-SCT in 1999 and 2005. They were identified from the British Society of Blood and Marrow Transplantation (BSBMT) (n=211 and n=453) and EBMT (n=1311 and n=1978) registries. An improvement in Day+100 and D+365 non-relapsed mortality (NRM) was shown between years 1999 and 2005 (P=0.0495). The 4-year relapse rate (RR) was significantly higher in 2005 (P=0.0003) and was associated with a shorter time to next treatment (TTNT) (P=0.025). The 4-year PFS was significantly lower in 2005 (P=0.0012), with the year of auto-SCT (P=0.001) and status at auto-SCT (P=0.02) being independently significant. The 4-year OS was similar between the year cohorts (P=0.266). In the 'benchmarking' comparison, the European Group for Blood and Marrow Transplantation (EBMT) 1999 cohort demonstrated the best PFS, although no year-of-transplant effect could be demonstrated on the 4-year OS rates (P=0.760). An improvement in supportive care resulting in reduced NRM is evident between the decades. The main cause of treatment failure remains disease progression. The similarity in OS between the years may reflect the introduction of novel agents in salvage therapy. The reduced PFS in 2005 is as yet not fully explained, but may represent recent disease response criterion standardization.
PMID: 21102497
ISSN: 1476-5365
CID: 3696022

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Dimopoulos, M A; Palumbo, A; Attal, M; Beksaç, M; Davies, F E; Delforge, M; Einsele, H; Hajek, R; Harousseau, J-L; da Costa, F Leal; Ludwig, H; Mellqvist, U-H; Morgan, G J; San-Miguel, J F; Zweegman, S; Sonneveld, P
An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreed that Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone. Recommendations regarding the prevention and management of adverse events, particularly venous thromboembolism and myelosuppression, were provided on the basis of the available evidence and practical experience of panel members. Ongoing trials will provide more insight into the effects of continuous lenalidomide-based therapy in myeloma.
PMID: 21293488
ISSN: 1476-5551
CID: 3696052

Guidelines for the diagnosis and management of multiple myeloma 2011

Bird, Jennifer M; Owen, Roger G; D'Sa, Shirley; Snowden, John A; Pratt, Guy; Ashcroft, John; Yong, Kwee; Cook, Gordon; Feyler, Sylvia; Davies, Faith; Morgan, Gareth; Cavenagh, Jamie; Low, Eric; Behrens, Judith
PMID: 21569004
ISSN: 1365-2141
CID: 3696062

Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma

Ishak, K Jack; Caro, J Jaime; Drayson, Mark T; Dimopoulos, Meletios; Weber, Donna; Augustson, Bradley; Child, J Anthony; Knight, Robert; Iqbal, Gulnaz; Dunn, Janet; Shearer, Arran; Morgan, Gareth
OBJECTIVES/OBJECTIVE:In some trials, particularly in oncology, patients whose disease progresses under the comparator treatment are crossed over into the experimental arm. This unplanned crossover can introduce bias in analyses because patients who crossover likely have a different prognosis than those who do not cross over; for instance, sicker patients not responding to standard therapy or those expected to benefit the most may be selectively chosen to receive the experimental treatment. Standard statistical methods cannot adequately correct for this bias. We describe an approach designed to minimize the impact of crossover, and illustrate this by using data from two randomized trials in multiple myeloma (MM). METHODS:The MM-009/010 trials compared lenalidomide and high-dose dexamethasone (Len+Dex) with dexamethasone alone (Dex). Nearly half (47%) of the patients randomized to Dex crossed over to Len with or without Dex (Len+/-Dex) at disease progression or study unblinding. Data from these trials was used to predict survival in an economic model evaluating the cost-effectiveness of lenalidomide. To adjust for crossover, the prediction equations were calibrated to match survival with Dex or Dex-equivalent therapies in trials conducted by the Medical Research Council (MRC) in the United Kingdom. To adjust for differences between the MM and MRC trial populations, a prediction equation was developed from the MRC data and used to predict survival by setting predictors to mean values for patients in the MM-009/010 trials. The expected survival with Dex without crossover was then predicted from the calibrated MM-009/010 equation (i.e., adjusted to match survival predicted from the MRC equation). RESULTS:The adjusted median overall survival predicted by the MRC equation was 19.5 months (95%CI, 16.6-22.9) for patients with one prior therapy, and 11.6 months (95% CI, 9.5-14.2) for patients with >1 prior therapy. These estimates are considerably shorter than was observed in the clinical trials: 33.6 months (27.1-NE) and 27.3 months (95% CI, 23.3-33.3) as of December 2005. CONCLUSION/CONCLUSIONS:The calibration method described here is simple to implement, provided that suitable data are available; it can be implemented with other types of endpoints in any therapeutic area.
PMID: 21839405
ISSN: 1524-4733
CID: 3696092

Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma

Walker, Brian A; Wardell, Christopher P; Chiecchio, Laura; Smith, Emma M; Boyd, Kevin D; Neri, Antonino; Davies, Faith E; Ross, Fiona M; Morgan, Gareth J
We used genome-wide methylation microarrays to analyze differences in CpG methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS], presentation myeloma, and plasma cell leukemia). We show that methylation patterns in these cell types are capable of distinguishing nonmalignant from malignant cells and the main reason for this difference is hypomethylation of the genome at the transition from MGUS to presentation myeloma. In addition, gene-specific hypermethylation was evident at the myeloma stage. Differential methylation was also evident at the transition from myeloma to plasma cell leukemia with remethylation of the genome, particularly of genes involved in cell-cell signaling and cell adhesion, which may contribute to independence from the bone marrow microenvironment. There was a high degree of methylation variability within presentation myeloma samples, which was associated with cytogenetic differences between samples. More specifically, we found methylation subgroups were defined by translocations and hyperdiploidy, with t(4;14) myeloma having the greatest impact on DNA methylation. Two groups of hyperdiploid samples were identified, on the basis of unsupervised clustering, which had an impact on overall survival. Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups.
PMID: 20944071
ISSN: 1528-0020
CID: 3647692

Heterogeneity in the prognostic significance of 12p deletion and chromosome 5 amplification in multiple myeloma [Letter]

Tapper, William; Chiecchio, Laura; Dagrada, Gian Paolo; Konn, Zoe J; Stockley, David M; Szubert, Alex J; Gregory, Walter M; Bell, Susan E; Jackson, Graham H; Child, J Anthony; Morgan, Gareth J; Ross, Fiona M
PMID: 21135272
ISSN: 1527-7755
CID: 3647702

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma

Johnson, David C; Corthals, Sophie L; Walker, Brian A; Ross, Fiona M; Gregory, Walter M; Dickens, Nicholas J; Lokhorst, Henk M; Goldschmidt, Hartmut; Davies, Faith E; Durie, Brian G M; Van Ness, Brian; Child, J Anthony; Sonneveld, Pieter; Morgan, Gareth J
PURPOSE/OBJECTIVE:To indentify genetic variation that can modulate and predict the risk of developing thalidomide-related peripheral neuropathy (TrPN). PATIENTS AND METHODS/METHODS:We analyzed DNA from 1,495 patients with multiple myeloma. Using a custom-built single nucleotide polymorphism (SNP) array, we tested the association of TrPN with 3,404 SNPs. The SNPs were selected in predicted functional regions within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and adverse effects associated with myeloma and its therapy. Patient cases and controls were derived from two large clinical trials that compared thalidomide with conventional-based treatment in myeloma patients (Medical Research Council Myeloma-IX and HOVON-50/GMMG-HD3). RESULTS:We report TrPN associations with SNPs-ABCA1 (rs363717), ICAM1 (rs1799969), PPARD (rs2076169), SERPINB2 (rs6103), and SLC12A6 (rs7164902)-where we show cross validation of the associations in both trials. To investigate whether TrPN SNP associations were related to exposure to thalidomide only or general drug-related peripheral neuropathy, we performed a second analysis on patients treated with vincristine. We report SNPs associated with vincristine neuropathy, with a seemingly distinct underlying genetic mechanism. CONCLUSION/CONCLUSIONS:Our results are consistent with the hypothesis that an individual's risk of developing a peripheral neuropathy after thalidomide treatment can be mediated by polymorphisms in genes governing repair mechanisms and inflammation in the peripheral nervous system. These findings will contribute to the development of future neuroprotective strategies with thalidomide therapy and the better use of this important compound.
PMID: 21245421
ISSN: 1527-7755
CID: 3647712

An early computed tomography-guided antifungal treatment strategy is safe and efficacious in patients undergoing chemotherapy for high-risk acute leukemia [Comment]

Mohammed, Kabir; Dignan, Fiona; Ethell, Mark E; Davies, Faith E; Morgan, Gareth J; Riley, Unell; Evans, Steve; Potter, Michael N; Shaw, Bronwen E
PMID: 21281242
ISSN: 1029-2403
CID: 3647722

Structure of the Ire1 autophosphorylation complex and implications for the unfolded protein response

Ali, Maruf M U; Bagratuni, Tina; Davenport, Emma L; Nowak, Piotr R; Silva-Santisteban, M Cris; Hardcastle, Anthea; McAndrews, Craig; Rowlands, Martin G; Morgan, Gareth J; Aherne, Wynne; Collins, Ian; Davies, Faith E; Pearl, Laurence H
Ire1 (Ern1) is an unusual transmembrane protein kinase essential for the endoplasmic reticulum (ER) unfolded protein response (UPR). Activation of Ire1 by association of its N-terminal ER luminal domains promotes autophosphorylation by its cytoplasmic kinase domain, leading to activation of the C-terminal ribonuclease domain, which splices Xbp1 mRNA generating an active Xbp1s transcriptional activator. We have determined the crystal structure of the cytoplasmic portion of dephosphorylated human Ire1α bound to ADP, revealing the 'phosphoryl-transfer' competent dimeric face-to-face complex, which precedes and is distinct from the back-to-back RNase 'active' conformation described for yeast Ire1. We show that the Xbp1-specific ribonuclease activity depends on autophosphorylation, and that ATP-competitive inhibitors staurosporin and sunitinib, which inhibit autophosphorylation in vitro, also inhibit Xbp1 splicing in vivo. Furthermore, we demonstrate that activated Ire1α is a competent protein kinase, able to phosphorylate a heterologous peptide substrate. These studies identify human Ire1α as a target for development of ATP-competitive inhibitors that will modulate the UPR in human cells, which has particular relevance for myeloma and other secretory malignancies.
PMCID:3049214
PMID: 21317875
ISSN: 1460-2075
CID: 3647732